Education
About Us
Working with TipRanks
Follow Us
Opko Health Inc (OPK)
NASDAQ:OPK
OPK Stock Chart & Stats
$1.53
-$0.03(-1.99%)
At close: 4:00 PM EST
$1.53
-$0.03(-1.99%)
Day’s Range― - ―
52-Week Range$1.11 - $2.04
Previous CloseN/A
Volume574.71K
Average Volume (3M)2.18M
Market Cap
$982.66M
Enterprise Value$1.18B
Total Cash (Recent Filing)$415.20M
Total Debt (Recent Filing)$395.42M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Feb 19, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding767,701,300
10 Day Avg. Volume1,466,492
30 Day Avg. Volume2,176,778
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)0.75
Price to Sales (P/S)1.43
P/FCF Ratio-4.89
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue1.83
Enterprise Value/Gross Profit4.75
Enterprise Value/Ebitda26.10
Forecast
1Y Price Target
$2.75Price Target Upside79.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diagnostics Product Growth4Kscore prostate cancer test has shown meaningful increases in test volume and revenue and is positioned for further uptake following a label expansion.
Financial PositionSale of oncology and diagnostic assets provided a substantial cash infusion that supports pipeline investment and reduces near-term financing pressure.
Partnerships And LicensingLicense and collaboration with Regeneron for ModeX technology includes upfront and milestone payments, presenting upside that could exceed $1 billion if programs progress successfully.
Bears Say
Clinical Development RiskThe broader clinical-stage drug portfolio remains early in development and requires clinical proof-of-concept before attracting significant investor confidence.
Diagnostic Volume DeclineDiagnostic services experienced a noticeable year-over-year decline in clinical test volume, pressuring segment revenue and profitability.
Earnings And MarginsTotal revenue fell short of analyst expectations and was accompanied by weaker gross margin and higher operating expenses, contributing to a slight bottom-line miss excluding one-time gains.
Opko Health News
OPK FAQ
What was Opko Health Inc’s price range in the past 12 months?
Opko Health Inc lowest stock price was $1.11 and its highest was $2.04 in the past 12 months.
What is Opko Health Inc’s market cap?
Opko Health Inc’s market cap is $982.66M.
When is Opko Health Inc’s upcoming earnings report date?
Opko Health Inc’s upcoming earnings report date is Feb 19, 2026 which is in 43 days.
How were Opko Health Inc’s earnings last quarter?
Opko Health Inc released its earnings results on Oct 29, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.06 by $0.09.
Is Opko Health Inc overvalued?
According to Wall Street analysts Opko Health Inc’s price is currently Undervalued.
Does Opko Health Inc pay dividends?
Opko Health Inc does not currently pay dividends.
What is Opko Health Inc’s EPS estimate?
Opko Health Inc’s EPS estimate is -0.07.
How many shares outstanding does Opko Health Inc have?
Opko Health Inc has 767,701,300 shares outstanding.
What happened to Opko Health Inc’s price movement after its last earnings report?
Opko Health Inc reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.06. Following the earnings report the stock price went up 2.098%.
Which hedge fund is a major shareholder of Opko Health Inc?
Currently, no hedge funds are holding shares in OPK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opko Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.75 (79.74% Upside)
$2.75 (79.74% Upside)
Blogger Sentiment
Bullish
OPK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 6.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $891.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.3%
Last 30 Days ▼ 10.4%
Last 30 Days ▼ 10.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.00%
12-Months-Change
Fundamentals
Return on Equity
-13.32%
Trailing 12-Months
Asset Growth
-0.35%
Trailing 12-Months
Company Description
Opko Health Inc
Opko Health, Inc. is a diversified healthcare company focused on developing and commercializing innovative health solutions. The company operates primarily in the pharmaceuticals and diagnostics sectors, offering a range of products including proprietary pharmaceuticals, diagnostic products, and novel drug delivery systems. Opko Health is known for its commitment to advancing medical technology and improving patient outcomes through its core products such as the 4Kscore Test, a diagnostic test for prostate cancer, and a portfolio of pharmaceutical products that address various medical needs.
OPK Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong strategic moves such as the sale of non-core assets and significant partnerships, contributing to financial improvements and shareholder value. However, there are challenges in diagnostics revenue decline and slower-than-expected market conversion affecting Pfizer profit share.View all OPK earnings summariesOPK Stock 12 Month Forecast
Average Price Target
$2.75
▲(79.74% Upside)
Technical Analysis
Ownership Overview
46.12% Insiders
6.49% Mutual Funds
8.53% Other Institutional Investors
28.44% Public Companies and
Individual Investors